Scientists hunt for clues to lung cancer drug resistance
NCT ID NCT03969823
First seen Apr 25, 2026 · Last updated May 12, 2026 · Updated 2 times
Summary
This study looks at why advanced lung cancer with a specific gene change (EGFR mutation) stops responding to the targeted drug osimertinib. About 148 adults will take osimertinib daily, and researchers will analyze tumor samples when the cancer progresses. The goal is to find new ways to overcome drug resistance and improve treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Borame Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam, South Korea
-
Seoul National University Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.